Abstract
Multiple myeloma (MM) is a B-cell malignancy characterized by an accumulation of long-lived neoplastic plasma cells (PC) within the bone marrow (BM). Novel treatments are not only targeting myeloma cells but also directly interfere with myeloma-stromal cell interactions, interrupting signal transduction pathways. Farnesyltransferase inhibitors (FTIs) and rapamycin represent novel classes of signal transduction inhibitors targeting principally Ras/MAPK and PI3K/Akt pathway. Pre-clinical and early clinical reports are presented in this study.
Keywords: CAAX binding site, Tipifarnib, STAT3 tyrosine phosphorylation, mTOR Kinase pathway, CCI-779, haematological malignancies
Current Pharmaceutical Biotechnology
Title: Farnesyltransferase Inhibitors and Rapamycin in the Treatment of Multiple Myeloma
Volume: 7 Issue: 6
Author(s): Maurizio Zangari, Federica Cavallo and Guido Tricot
Affiliation:
Keywords: CAAX binding site, Tipifarnib, STAT3 tyrosine phosphorylation, mTOR Kinase pathway, CCI-779, haematological malignancies
Abstract: Multiple myeloma (MM) is a B-cell malignancy characterized by an accumulation of long-lived neoplastic plasma cells (PC) within the bone marrow (BM). Novel treatments are not only targeting myeloma cells but also directly interfere with myeloma-stromal cell interactions, interrupting signal transduction pathways. Farnesyltransferase inhibitors (FTIs) and rapamycin represent novel classes of signal transduction inhibitors targeting principally Ras/MAPK and PI3K/Akt pathway. Pre-clinical and early clinical reports are presented in this study.
Export Options
About this article
Cite this article as:
Zangari Maurizio, Cavallo Federica and Tricot Guido, Farnesyltransferase Inhibitors and Rapamycin in the Treatment of Multiple Myeloma, Current Pharmaceutical Biotechnology 2006; 7 (6) . https://dx.doi.org/10.2174/138920106779116838
DOI https://dx.doi.org/10.2174/138920106779116838 |
Print ISSN 1389-2010 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4316 |
Call for Papers in Thematic Issues
Artificial Intelligence in Bioinformatics
Bioinformatics is an interdisciplinary field that analyzes and explores biological data. This field combines biology and information system. Artificial Intelligence (AI) has attracted great attention as it tries to replicate human intelligence. It has become common technology for analyzing and solving complex data and problems and encompasses sub-fields of machine ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
miR-137 Suppresses the Phosphorylation of AKT and Improves the Dexamethasone Sensitivity in Multiple Myeloma Cells Via Targeting MITF
Current Cancer Drug Targets Designed Multiple Ligands: Basic Research vs Clinical Outcomes
Current Medicinal Chemistry Adverse Effects of Tacrolimus in Renal Transplant Patients from Living Donors
Current Drug Safety Is Going for Cure in CML Targeting Aberrant Glycogen Synthase Kinase 3β?
Current Drug Targets Naphthalimides and Azonafides as Promising Anti-Cancer Agents
Current Medicinal Chemistry Mitochondrial Physiology and Toxicity (Mitotoxicity); Importance for the Immune System, Programmed Cell Death and Cancer
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents The Effect of Casein Kinase 2 Inhibition on three Leukemic Cell Lines
Current Drug Therapy Targeting Blood Vessels for the Treatment of Non-Small Cell Lung Cancer
Current Cancer Drug Targets Nutritional Support in Cancer
Current Nutrition & Food Science SNAP-tag based Agents for Preclinical In Vitro Imaging in Malignant Diseases
Current Pharmaceutical Design Polo-Like Kinase 1 Pharmacological Inhibition as Monotherapy or in Combination: Comparative Effects of Polo-Like Kinase 1 Inhibition in Medulloblastoma Cells
Anti-Cancer Agents in Medicinal Chemistry Molecular Mechanisms of Pancreatic Cancer Dissemination: The Role of the Chemokine System
Current Pharmaceutical Design Dasatinib: An Anti-Tumour Agent via Src Inhibition
Current Drug Targets Safety and Efficacy of Immune Checkpoint Inhibitors in Children and Young Adults with Haematological Malignancies: Review and Future Perspectives
Cardiovascular & Hematological Agents in Medicinal Chemistry Targeted Therapy of Ovarian Cancer with Angiogenesis Inhibitors
Current Drug Targets Rituximab The First Monoclonal Antibody Approved for the Treatment of Lymphoma
Current Pharmaceutical Biotechnology Editorial (Thematic Issue: The Effects of Anticancer Agents on Cell Apoptosis and on the Expression of Cancer - Related Genes)
Anti-Cancer Agents in Medicinal Chemistry Survivin: Role in Normal Cells and in Pathological Conditions
Current Cancer Drug Targets Therapeutic Applications of Mesenchymal Stem Cells: A Comprehensive Review
Current Stem Cell Research & Therapy Depression has a Strong Relationship to Alterations in the Immune, Endocrine and Neural System
Current Psychiatry Reviews